CMCS activated peritoneal macrophages to promote phagocytosis of murine hepatocellular cancer cells in vivo, and orally administered CMCS significantly slowed the tumor growth in mice bearing BEL‐7402 and hepatoma 22 cells by down‐regulation of vascular endothelial growth factor (VEGF) and MMP‐9 in tumors.[360] Liang et al. Here, VEGFA is linked to hepatocellular carcinoma.